In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels

Tanja Rothgangl(University of Zurich), Gerald Schwank(University of Zurich), Rurika Oka(University of Amsterdam), Anastasia P. Kadina(Synthego (United States)), Denis V. Victorov(Synthego (United States)), Noëlle Bakker(University of Zurich), Markus Stoffel(University of Zurich), Ruben van Boxtel(Oncode Institute), Zacharias Kontarakis(ETH Zurich), Sabina Egli(University of Zurich), John Walker(Synthego (United States)), Sean C. Semple(Arbutus Biopharma (Canada)), Costanza Borrelli(ETH Zurich), Kevin Holden(Synthego (United States)), Paulo J.C. Lin(University of British Columbia), Nina Frey(University of Zurich), Andreas E. Moor(Weizmann Institute of Science), Dominik Witzigmann(FPInnovations), Martina Hruzova(ETH Zurich), Johannes Häberle(University Children's Hospital Zurich), Ying K. Tam(Arbutus Biopharma (Canada)), Melissa K. Dennis(Acuitas Therapeutics (Canada)), Susanne Kreutzer(University of Zurich), Norbert Pardi(University of Pennsylvania), Drew Weissman(California University of Pennsylvania), Beat Thöny(Swiss Integrative Center for Human Health), Martin Pačesa(SIB Swiss Institute of Bioinformatics), Daniela Lenggenhager(University of Zurich), Weihong Qi(University of Zurich), Martin Jínek(University of Zurich), Lucas Kissling(University of Zurich), Lukas Villiger(McGovern Institute for Brain Research)
Nature Biotechnology
May 19, 2021
Cited by 375


Related Papers